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1.31), p=0.91; 74Gy vs 57Gy: HR 1.02 (0.74-1.30), p=0.86). 
Analysis of change from pre-RT showed no evidence of a 
difference between treatment groups (figure 1).  
 
 
 
The odds of an increase in overall bowel bother were reduced 
(compared to the 74Gy control arm) by 11% (odds ratio (OR) 
0.89 99% CI: (0.62-1.27), p=0.4) and 8% (OR 0.92 (0.77-1.10), 
p=0.24) in the 60Gy and 57Gy groups respectively. For overall 
urinary bother, odds of an increase were increased by 31% 
(OR 1.31, (0.93-1.85) p=0.04) and 2% (OR 1.02 (0.86-1.20), 
p=0.79) for the 60Gy and 57Gy groups respectively. 
Conclusions: Overall bowel bother and overall urinary bother 
was low in the CHHiP trial, cross sectional and longitudinal 
analysis found no evidence of differences between either 
hypofractionated arm and the 74Gy control arm to 24 months 
of follow up.  
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Purpose/Objective: To evaluate the feasibility and 
preliminary toxicity results of a prospective randomized 
multicenter phase II trial of short vs. protracted urethra-
sparing stereotactic body radiotherapy (SBRT) for localized 
prostate cancer. 
Materials and Methods: A total of 93 cT1-3a N0 M0 prostate 
cancer patients with a lymph-node involvement risk ≤ 20% 
were randomized between September 2012 and October 2014 
to be treated with an SBRT protocol of 36.25 Gy in 5 fractions 
of 7.25 Gy either over 9 days (Arm A, n=45) or over 28 days 
once-a-week, the same week-day (Arm B, n=48). The dose to 
the prostatic urethra with a surrounding margin of 3 mm 
(urethral planning risk volume, uPRV) was reduced to 32.5 Gy 
in 5 fractions (NTD2Gy of 74 and 62 Gy for an α/β ratio of 1.5 
and 3 Gy, respectively). Tolerance to the treatment was 
scored using the Common Toxicity Criteria for Adverse Events 
ver. 4.0 grading scale, the International Prostate Symptom 
Score (IPSS) and the EORTC QLQ-PR25 quality of life (QoL) 
questionnaire. Thirty-seven patients in Arm A and 38 patients 
in Arm B have completed treatment. Their follow-up (FU) 
extended up to 18 months and in Arm A 70% has reached their 
six month evaluation, while 60% of the patients in Arm B did. 
Results: SBRT was delivered to all patients as planned with 
no treatment interruptions. Overall genitourinary and 
gastrointestinal toxicities were below the stopping rule 
established for the study, with grade 2 toxicity reported in 6 
patients for each arm mostly after the 5th fraction. Only one 
patient experienced late grade 3 rectal toxicity, with the 
need of blood transfusion and endoscopic coagulation for the 
bleeding, between the 7th and 12th month FU. Mean IPSS 
scores increased significantly between baseline and the 5th 
fraction (p<0.01) in both treatment arms, returning to 
baseline at week 12. Mean IPSS values at baseline, after the 
5th fraction and after 12 weeks were 7.5, 14 and 7.5 for Arm 
A and 8.1, 12.7 and 8.9 for Arm B, respectively. No 
significant differences were observed in EORTC QLQ-PR25 
QoL endpoints between baseline and week 12 in either study 
arm.  
Conclusions: Preliminary results demonstrated the feasibility 
and the acceptable toxicity rates of this short vs. protracted 
urethra-sparing prostate SBRT phase II trial. Three months 
after randomization complete recovery from side effects and 
return to baseline IPSS scores was observed in both treatment 
schedules.  
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Purpose/Objective: The combination of adjuvant hormone 
therapy (HT) with radiotherapy (RT) improves prognosis in 
patients with intermediate-high risk prostate cancer (PCa). 
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However, some studies showed that adjuvant HT may be 
associated with worse radio-induced toxicity although this 
topic remains controversial. Therefore, the purpose of this 
study was to evaluate the impact of the HT (in terms of drug 
type and duration) on acute and late toxicity in patients 
undergoing RT for PCa. 
Materials and Methods: We collected data from 8 clinical 
trials on RT of PCa. Acute toxicity was assessed according to 
the RTOG scale and late toxicity according to RTOG-EORTC 
scale. The results in terms of acute toxicity were compared 
with the chi-square test. Late toxicity actuarial cumulative 
incidence was calculated by Kaplan-Meier method and the 
comparison between survival curves was performed using log-
rank test (univariate analysis) and Cox's Proportional Hazard 
Method (multivariate analysis using as covariates: RT dose, 
fractionation and prophylactic lymph node irradiation).  
Results: Overall 346 patients were included in this analysis 
(median age: 72 years, range: 50-82; median RT dose: 70 Gy, 
range: 65-80; LH-RH analogue: 51.4%, high-dose antiandrogen 
[bicalutamide 150 mg/die]: 48.6%; HT for 6 months: 50.3%, 
HT for 24 months: 49.7%). The results of the statistical 
analysis are shown in the table. 
 
 
 
The higher incidence of GI late toxicity in patients receiving 
adjuvant hormone therapy with LH-RH analogue was 
confirmed by multivariate analysis (p: 0.038). 
Conclusions: In an evaluation of radiation-induced toxicity in 
patients undergoing RT plus adjuvant HT, a higher incidence 
of late GI toxicity was recorded in patients treated with LH-
RH analogues compared with patients treated with 
antiandrogen. This result warrants further studies to optimize 
adjuvant therapies in patients with PCa.  
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Purpose/Objective: To assess the toxicity of combined 
therapy between external beam radiation therapy (EBRT) 
plus high dose rate brachytherapy (HDRB) as a boost in 
patients with intermediate or high risk prostate cancer. 
Materials and Methods: From 2010 to August 2014, a total of 
221 patients diagnosed as intermediate or high-risk prostate 
cancer were treated with EBRT plus HDRB. Median age was 72 
years (range 52-85). Most patients (68%) were classified as 
high-risk (stage T2c-T3b or PSA >20ng/dl or GS>7), and 70 
patients (32%) were considered intermediate risk. The stage 
of tumor was determined in every case by magnetic 
resonance imaging (MRI). Every patient received first HDRB as 
boost and 4 gold fiducials were implanted. Finally, all 
patients received EBRT by intensity modulated radiotherapy 
technique with imaging guided by CBCT. The patients 
received HDRB as a single 15 Gy implant, followed by EBRT to 
46 Gy in 23 fractions. Thirty seven percent of the high-risk 
patients presented seminal vesicles invasion receiving a 
single 9.5 Gy implant, followed by ERBT to 60 Gy in 30 
fractions. A total of 117 patients (52%) received a dose of 46 
Gy to the true pelvis. In all brachytherapy plans, the 
constraints indicated in the GEC/ESTRO recommendations 
have been respected (Rectum D2cc £75Gy EQD2; Urethra 
D10£ 120Gy EQD2). Most patients (120; 54%) were prescribed 
complete androgen deprivation therapy (ADT), 66 (29%) 
received incomplete ADT and 28 (13%) did not receive ADT. 
GI and GU toxicity was evaluated utilizing the RTOG criteria. 
Median follow-up was 26 months. 
Results: No treatment failure has been observed to the last 
follow-up. The incidences of any acute ≥ Grade 2 GI or GU 
toxicities were 0% and 9% respectively. Dysuria and urgency 
was prevalent symptoms in acute GU toxicity. Late 
genitourinary toxicity included 2 patients (0.9%) with urine 
obstruction requiring intermittent/permanent catheter. One 
case of grade 2 gastrointestinal late toxicity presented 
actinic rectitis event. 
Conclusions: The use of a single 15Gy fraction HDRB as pre-
treatment EBRT boost provides early-term and good 
outcomes in treatment-related toxicity. These data can help 
physicians to assess this scheme of radiotherapy as an 
acceptable option in the prostate carcinoma treatment.  
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Purpose/Objective: The use of hypofractionation allows to 
reduce the duration of radiotherapy (RT) and is theorically 
associated with an improved probability of cure in patients 
with prostate cancer (CAP). However, hypofractionated RT 
could be associated to an higher incidence of late side 
effects. Several studies are in progress to valuate efficacy of 
this irradiation modality but there are no definitive 
indications about tolerability and efficacy of this 
